Get the Stockscreener App
0.1511
9.30%
-0.0155
After Hours:
.16
0.0089
+5.89%
Azitra Inc stock is traded at $0.1511, with a volume of 1.75M.
It is down -9.30% in the last 24 hours and down -30.05% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.1666
Open:
$0.1607
24h Volume:
1.75M
Relative Volume:
0.16
Market Cap:
$2.45M
Revenue:
$7,500
Net Income/Loss:
$-10.96M
P/E Ratio:
-0.0659
EPS:
-2.2943
Net Cash Flow:
$-11.41M
1W Performance:
-8.81%
1M Performance:
-30.05%
6M Performance:
-45.78%
1Y Performance:
-40.63%
1-Day Range:
$0.1507
$0.1661
1-Week Range:
$0.1507
$0.177
52-Week Range:
$0.10
$1.40
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.1511 | 2.72M | 7,500 | -10.96M | -11.41M | -2.2943 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Azitra Inc Stock (AZTR) Latest News
Why Is AZTR Stock Rising Today? - Stocktwits
Azitra Inc Actuals & Estimates (AMEX:AZTR) - TradingView
Dauntless Investment Group buys stake in Azitra (AZTR) — 9.58% disclosed - Stock Titan
AZTR Forecast — Price Target — Prediction for 2027 - TradingView
Francisco D. Salva Discloses Investment at Azitra, Inc. with 9.99% Stake - TradingView
$Azitra (AZTR.US)$ - Moomoo
[SCHEDULE 13D] Azitra, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Azitra Inc (AZTR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Sagtec Global Shares Are Trading Higher By Around 76%; Here Are 20 Stocks Moving Premarket - Sahm
Azitra Inc (AZTR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 13G Azitra For: 22 June By Investing.com - Investing.com Australia
Stonepine group discloses 1.74M-share stake in Azitra (NASDAQ: AZTR) with 9.9% cap - Stock Titan
$Azitra (AZTR.US)$ tq aztr - Moomoo
Why Did Azitra (AZTR) Stock Jump Over 25% After Hours? - Benzinga
Azitra Inc (AZTR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Azitra (AZTR) CEO converts Series A preferred stock into common shares - Stock Titan
cant predict the pullback bottom. but you can predict the real buy and real sell zones based off market structure - Moomoo
12 Health Care Stocks Moving In Thursday's After-Market Session - Sahm
Azitra Inc (AZTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Azitra Inc (AZTR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Azitra Inc (AZTR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Recently, the CEO of Azitra Inc issued an open letter to shareholders, detailing the company's current strategic adjustments and providing an outlook on development prospects for 2026 and beyond. - Bitget
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strateg - GuruFocus
Azitra, Inc. Unveils Strategic Shift: New Cosmetic Ingredient Program and Biotech Expansion Set for 2026 Growth - Minichart
Azitra Announces Strategic Shift Toward Cosmetics and Biotech Tools - TipRanks
Azitra CEO outlines strategic reorientation, $10.5M financing, ATR-COSF and recombinant protein initiatives - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond - PR Newswire
Azitra's Pivot: From Pharma Pipeline to Biotech Platform - BriefGlance
Azitra Expands Authorized Shares Following Stockholder Approvals - TipRanks
Azitra Inc (AZTR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Azitra Inc (AZTR) Institutional Confidence - TradingKey
Azitra Inc (AZTR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Azitra, Inc. to Present at 2026 BIO International Convention - PR Newswire
Azitra's Big Gamble: From Rare Disease Cures to the Beauty Counter - BriefGlance
Azitra shareholders approve share increase and board proposals at annual meeting - Investing.com UK
Azitra, Inc. Files Form 8-K: Amendment to Certificate of Incorporation and Key Company Details (June 2026) - Minichart
Azitra shareholders approve share increase and board proposals at annual meeting By Investing.com - Investing.com South Africa
Azitra (NYSE: AZTR) wins votes for share increase and financing issuances - Stock Titan
AZTR Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin, Stock DeclinesEarnings Yield Analysis - newsline.com
AZTR Q1 2026 Earnings: Massive EPS Miss Highlights Operational ChallengesAnnual Financial Report - newsline.com
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Bu - GuruFocus
Azitra Adjourns 2026 Annual Meeting for Lack of Quorum - The Globe and Mail
Azitra (AZTR) delays 2026 annual meeting after low shareholder turnout - Stock Titan
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting - Nasdaq
[EFFECT] Azitra, Inc. SEC Filing - Stock Titan
Azitra Inc (AZTR) Slips 5% as Stock Tests Key Support Near $0.21Leveraged ETF Flow - newsline.com
Azitra Inc (AZTR) Surges 12%: Small-Cap Biotech Breaks Above SupportHead and Shoulders - thelegaladvocate.com
Azitra Inc Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; Stock Surges Amid No Revenue Reported - The Legal Advocate
Azitra Inc (AZTR) Surges 12%: Testing Key Resistance at $0.24Wyckoff Accumulation - The Legal Advocate
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.86%
Cap:
|
Volume (24h):